MAGIA DIAGNOSTICS

The traditional blood testing circuit starts with taking blood samples and moves on to analyses by robots and heavy equipment unsuitable for certain analyses, especially concerning emergency screenings and those of high-risk populations where delayed results affect patient care.

Its technology, combining magnetic nanoparticles and micromagnets integrated in its cartridge, means that the Magia Diagnostics test can detect up to three molecules simultaneously in fifteen minutes from a single drop of blood.

The portable Magia Diagnostics system makes it easy to transfer all existing immunological protocols while preserving their performance and reducing analysis time. Magia Diagnostics enables rapid decision-making based on the analysis of several parameters.

By the end of 2022 the startup will have industrial cartridge production running, and a pre-industrial version of a reader on which they will carry out their clinical validations. This will enable the compagny to obtain CE marking by 2024, and from then on they will enter the marketing and recurrent production phase. The team is more than 15 persons. Magia diagnostics has been selected within the French State Grand Défi for bioproduction and collaborates wiyh Toulouse White Technology and LRGP Lab.

As a first step, Magia Diagnostics is focusing on infectious diseases with the development of a test for the diagnosis of a hepatitis B sample group, and a test for the simultaneous diagnosis of HIV and Hepatitis B and C for better access to care.